This application is to evaluate promising new therapies for patients with malignant disease in a clinically efficient, regulatory-compliant, and scientifically rigorous research environment. Phase I clinical studies of new anti-cancer therapies continue to evolve as basic / translational research has broadened the targeted opportunities to treat malignant disease. Building upon a strong foundation in the conduct of phase I studies, we have assembled an interactive research team that uses rationally designed clinical trials that enhances the molecular / pharmacologic assessment of new drug activity. These trials and assessment methods are designed ultimately to impact on the clinical care of patients diagnosed with cancer. The overall objective of these Phase l/ll studies is to determine the appropriate dose and schedule of experimental agents for further evaluation of efficacy in solid tumor /hematologic malignancies and to characterize the acute and chronic toxicities of these anti-cancer therapies.
Our Specific Aims are 1) To conduct Phase I clinical trials of novel anti-cancer agents (alone or in combination) in a timely manner;2) To perform detailed pharmacokinetic studies of these new agents and to correlate these observations with relevant clinical I biologically sound endpoints;3) To implement correlative and pharmacodynamic laboratory evaluations in proof of drug mechanism phase I clinical trials and to explore optimal relationships between parameters of drug exposure and biological effects;and 4) To maintain a clinical trial infrastructure that is current and compliant with regulatory standards that assure quality care to patients enrolled on early phase clinical trials. Over the past 4 years, our UO1 Phase I program has enrolled over 500 patients (131 patients/year average), completed 12 trials, submitted 38 Letters of Intent, have 12 ongoing trials and 4 new trials approved, and have over 80 publications directly related to this Collaborative agreement. Our research group remains flexible to expansion and to explore other targets of interest / trial designs as well as well-positioned to further incorporate novel imaging into our early phase clinical trials. Given our productivity, experience, and expertise in early phase clinical trials, we fully expect to enroll 100 patients / year and to complete 2-3 phase l/ll clinical trials/ year via this cooperative agreement. Scientifically, members of our program will continue active participation in the Investigational Drug Steering Committee (IDSC).
|Reiss, Kim A; Herman, Joseph M; Zahurak, Marianna et al. (2015) A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res 21:68-76|
|Subhawong, Ty K; Jacobs, Michael A; Fayad, Laura M (2014) Insights into quantitative diffusion-weighted MRI for musculoskeletal tumor imaging. AJR Am J Roentgenol 203:560-72|
|Chaudhuri, Leena; Vincelette, Nicole D; Koh, Brian D et al. (2014) CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99:688-96|
|Pratz, Keith W; Luger, Selina M (2014) Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr Opin Hematol 21:72-8|
|Dufresne, Simon F; Marr, Kieren A; Sydnor, Emily et al. (2014) Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol 52:1830-7|
|De Jesus-Acosta, Ana; Laheru, Daniel; Maitra, Anirban et al. (2014) A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32:739-45|
|Ding, Husheng; McDonald, Jennifer S; Yun, Seongseok et al. (2014) Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica 99:60-9|
|Zeidner, Joshua F; Karp, Judith E; Blackford, Amanda L et al. (2014) A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica 99:672-8|
|El Khouli, Riham H; Macura, Katarzyna J; Kamel, Ihab R et al. (2014) The effects of applying breast compression in dynamic contrast material-enhanced MR imaging. Radiology 272:79-90|
|Kremer, Kimberly N; Dudakovic, Amel; McGee-Lawrence, Meghan E et al. (2014) Osteoblasts protect AML cells from SDF-1-induced apoptosis. J Cell Biochem 115:1128-37|
Showing the most recent 10 out of 80 publications